Low

Constant Contact Brings SMS Marketing To Australian Small Businesses

Constant Contact announced the launch of SMS marketing for small businesses and nonprofits in Australia, adding SMS to its existing email and social marketing platform. The company said SMS supports promotions, appointment reminders, loyalty messages, re-engagement campaigns, and targeted outreach for periods like EOFY. It is offered on a flat monthly fee, according to Constant Contact.

2/10
5/10
Low
ahead of Australia EOFY (lead-up to 30 June)
neutral (product launch/feature expansion; no public company-specific financial impact)

Background

Constant Contact announced the launch of SMS marketing for Australian small businesses, positioned as an add-on within its existing marketing platform.

Why it matters

The article is a marketing/feature launch and does not provide financial metrics, customer counts, or guidance that would translate into a tradable catalyst for a specific US-listed issuer.

Market relevance

Relevant mainly as sector/technology read-through for SMB marketing automation; limited direct trading signal without a US-listed public-market impact.

Market effects

Supports ongoing demand for SMB marketing automation and omnichannel messaging tools; modest positive read-through for marketing-tech vendors generally.

Direct go-to-market expansion into Australia could modestly increase competition for SMB SMS/email platforms ahead of EOFY.

If replicated internationally, reinforces a broader trend toward SMS as an additional conversion channel within marketing suites.

Alternative perspectives

SMS adoption may be incremental versus email/social; uptake could be limited by deliverability, compliance, and customer opt-in friction.

No evidence of pricing power, churn, or measurable ROI—launch announcements often precede slower, usage-driven monetization.

Key entities

  • Constant Contact

    Announced SMS marketing availability for Australian SMBs, with flat monthly pricing and use cases like promotions, reminders, loyalty, and re-engagement.

Related articles

$SLNMed

Silence Therapeutics plc: Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Silence Therapeutics (Nasdaq: SLN) reported follow-up and quality-of-life results for divesiran in its Phase 1 SANRECO study at EHA 2026 in 21 polycythemia vera patients. Phlebotomy use fell from 80 in the prior 6 months to 5 during treatment and 4 in 16-week follow-up; median time to first phlebotomy was 287 days. The company said Phase 2 SANRECO remains on track for topline results in Aug 2026.

$METALow

Meta Smartwatch Due September 23: Malibu 2 Doubles as Gesture Hub for Ray-Ban AI Glasses

Meta plans to unveil its first commercial smartwatch, codenamed Malibu 2, at Meta Connect 2026 on Sept. 23, 2026. The watch is expected to use surface electromyography for gesture control for Meta’s Ray-Ban AI glasses, while also tracking continuous heart rate, blood oxygen, sleep, and running a built-in Meta AI assistant without a required subscription. Sources cited by The Information say it will complement, not compete with, Meta’s glasses.

$PPBTMed

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Purple Biotech presented preclinical EACR 2026 data on its CAPTN-3 program, IM1240. A non-GLP NHP toxicology study validated the CAPTN-3 masking strategy, reporting ~8-fold longer half-life and 16-fold higher exposure versus the non-capped variant IM1222, with markedly lower cytokine release. In patient-derived PD-1/chemo-resistant tumor samples, IM1240 showed anti-tumor activity requiring CD3 and NKG2A, and in NSCLC explants induced mature tertiary lymphoid structures. The company plans first-i

$SNDXMed

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Syndax Pharmaceuticals reported multiple Revuforj (revumenib) abstracts at EHA 2026. In ROAR (R/R NPM1m/KMT2Ar), interim ORR was 82% (9/11) with 64% (7/11) CR/CRh. In SNDX-5613-0708 (newly diagnosed NPM1m/KMT2Ar), CRc was 97% (34/35) and MRD negativity 86% (25/29). Post-HSCT AUGMENT-101 analysis showed 12-month OS 95%. In SAVE (R/R AML), ORR was 88% (37/42) and MRD negativity 68% (25/37).

$GMMed

GM Activates 250,000 EVs for Vehicle-to-Grid: Sodium-Ion Batteries Target Grid-Peaker Replacement

General Motors said it activated vehicle-to-grid capability for more than 250,000 existing bidirectional EVs via over-the-air software, turning them into a software-dispatched “virtual power plant” for utilities during peak demand. GM is piloting with PG&E and DTE Energy and inviting other utilities. GM also partnered with Peak Energy on sodium-ion grid batteries, citing a Colorado 875 kW/3.5 MWh system and plans for prototypes by end-2026 and trial production in 2028.

$KMRKLow

K-Tech Solutions Company Limited and Aurora AZ Energy Ltd. Announce Construction and Testing Progress on Initial 5 MW Capacity Phase of Joint Venture

K-Tech Solutions (Nasdaq: KMRK) and Aurora AZ Energy said construction has started on a first 5 MW phase of their Alberta, Canada joint venture to deploy up to 500 MW of IT capacity. The companies also began onsite testing to validate integration of Aurora’s wellhead power with K-Tech’s computing systems. The 5 MW buildout is intended as proof-of-concept for a planned 100 MW flagship deployment.